Deadly West Nile Virus
For Profit - Vaccine
Award Announced
By Patricia Doyle <>
When I first began writing articles, and doing radio show interviews about the New York West Nile outbreak I mentioned the OraVax ompany in Cambridge, Mass. Unwittingly, in 1999, OraVax, and, its parent company, Peptide Therapeutic of Cambridge, UK, had an article on the corporate website regarding a chimeravax vaccine for Japanese Encephalitis family of flaviviruses. OraVax was to field test this vaccine in Fall 1999, which coincided with the outbreak of West Nile Fever in New York.
Plans for this vaccine were in the works prior to 1996. It was in 1996 when OraVax Co. was granted permission to license genetically altered Japanese Encephalitis which had been exclusively created and patented by the US government, Ft. Detrick.
It is no surprise that OraVax would get the Ft. Detrick altered encephalitis, and the subsequent grant to manufacture and market the vaccine.
I had further discussed an alliance between Dr. Jerry Hauer, former head of the Office of Emergency Management for New York City, and Col. Dr. Thomas Monath of OraVax. Both were from our biowar research facility at Ft. Detrick. Dr. Monath has been working closely with New York City OEM and the CDC from August when the outbreak was allegedly said to have begun.
OraVax had said on its own website that Phase 2 trials were scheduled to commence this Fall 2000. We now have breaking news that OraVax was granted 3 million dollars to develop a West Nile vaccine.
There have been those, like myself, who knew the vaccine was in the making and who suspected that the West Nile virus was released on the public to create a market for the vaccine. News of this grant further strengthens our suspicions that the outbreak was indeed ochestrated for 1. profit and 2. as a bioterrorism preparedness simulation and experiment.
I believe that is why the virus was "allegedly" released in New York. There have been many involved in bioterrorism preparedness who believe New York will be hit with a bioweapon and who, like Dr. Jerry Hauer, were vocal about the need for a real life simulation in the New York area.
I sincerely hope that our elected officials will make a sincere investigation into the origin of the non-endemic West Nile outbreak. If it is found that the virus was released on the public, I hope that those responsible will be held accountable. There were 7 deaths last year from the virus and it is estimated that there will be even more deaths this year. In my book that makes anyone releasing this virus a serial killer.
Thank you,
West Nile Virus Vaccine Announced
By Company Linked To Giuliani
The Financial Times - London 8-1-00
Peptide Therapeutics, the UK biotech company, said it had been awarded a $3m grant to develop a new vaccine to combat the mosquito-borne West Nile virus, which killed seven The vaccine will be developed at OraVax, Peptide's US subsidiary, using the company's proprietary ChimeriVax technology." [see below for their detailed press release]
For the past 10 months I have been writing about a bio-chemical corporation, Oravax, in relation to the so-called WNV (West Nile Virus) epidemic in NYC. The V.P of Oravax, Dr. Thomas Monath has been working behind the scenes with Mayor Giuliani, former OEM chief Jerry Hauer, Dr. Cohen and the CDC since the very beginning of this issue.
From: Newsday 9/25/99-Deadly Discovery "Virologist Thomas Monath, one of the country's leading authorities on mosquito-carried viruses, called the discovery ``a bombshell,'' and added: `` This is the biggest arbovirus story of the last 50 years. Wow!'' Monath, who works for OraVax, a biotechnology company in Boston, said he has been working closely with CDC investigators in New York since the encephalitis outbreak began in late August. He is assisting federal scientists in trying to figure out a way to deal with the new development."<
As predicted, Oravax has now been given a grant from the N.I.H. (National Institute of Health) to create a WNV vaccine. The theory I and a number of other activists have been suggesting is that the entire WNV panic has been created specifically in order to justify the mass distribution of this very vaccine throughout the entire U.S.
Oravax was granted a license by the U.S. Army bio-warfare lab in Ft. Dietrick in 1996 (Monath was previously a researcher at the same lab) to manufacture a Japanese encephalitis vaccine derived from a genetically-altered virus the Army itself created. WNV is a variation of Japanese encephalitis. Numerous medical and scientific institutions, many run by the Federal government, have been quietly experimenting with WNV in NYC and the surrounding area for decades [see references below]. Most of this research involved bio-warfare applications.
According to the press release and articles below the vaccine is a live, attenuated vaccine (it contains live WN virus) and involves "the construction of a chimeric virus in which the envelope genes of yellow fever vaccine are replaced with the corresponding genes of the target West Nile virus". In other words, the plan appears to be to expose the entire nation orally to a genetically-modified form of WNV.
Since the vaccine is made from a genetically-altered strain there is no way to know exactly what other theoretically beneficial or harmful genes may have been added. Scientists in the field of GE foods (genetically-altered foods) have already found evidence that genes in the pollen of these foods can become incorporated into the DNA of insects that pollinate the GE plants. In other words it is possible to incorporate these genes into your own DNA simply by eating the food, or in this instance, orally taking a vaccine. _____
From: "Tappeser" < Organization: Oeko-Institute e.V.
Subject: new stories from Germany
"The German Television ZDF reported on Sunday May 21 that a German researcher found a gene transfer from genetically engineered rapeseed to bacteria and fungi in the gut of honey bees. Prof. Hans-Hinrich Kaatz from the Institut fºr Bienenkunde (Institute for bee research) at the University of Jena experimented during the last three years with honey bees on an experimental field with transgenic rapeseed in Saxony, Germany."
Mayor Giuliani and his advisors have been massively spraying NYC with a variety of toxic pesticides since last Fall, despite knowing that experts in the field of mosquito control have determined that such spraying actually increases the number of mosquitoes, makes succeeding generations pesticide resistant and increases the incidence of mosquitoes infected with transmissible viruses like WNV by as much as 15 times. [see: Are Mosquito Spray Pesticides Worsening the Encephalitis Problem? SOURCE: Journal of the American Mosquito Control Assoc, Dec;13(4):315-25, 1997 Howard JJ, Oliver New York State Department of Health, SUNY-College ESF, Syracuse 13210, USA. Also see my articles on this]
Considering the mild nature of WNV their actions appear to be intended to increase WNV rather than to decrease it. Dr. Cohen implied as much two days ago. _____
Spray It Ain't So! Round 2 On S.I.
New York Post 8-1-00
"Cohen said...Part of the reason for the new skeeter woes is that between 10 and 20 percent of the bugs won't be killed by the pesticide [the ones that are resistant to the chemicals] - and those that live will reproduce, Cohen said....Cohen said the traps were nearly empty in the first two days after the initial Staten Island spraying last month, but now they're filling up again."This is not unexpected," he insisted."
That Dr. Cohen acknowledges he knows that the spraying would lead to new generations of pesticide resistant mosquitoes supports the idea that the spraying is actually intended to help create a demand for the vaccine, which the NYC officials unquestionably knew was already in development and testing. What the real purpose of the vaccine is one can only guess at this point. _____
Germ Defense Plan In Peril As Its Flaws Are Revealed
New York Times 8-7-98
If you carefully read the very long article this is excerpted from you will see detailed evidence of how Dr. Monath, former Giuliani OEM chief Jerry Hauer, the president of Rockefeller University (where they have experimented with WNV for decades) and Dr. J. Craig Venter, president of The Institute for Genomic Research (the co-researchers and co-owners of the Human Genome Project) have been pressuring President Clinton to spend billions on a nationwide vaccine program against germ warfare.
"In April, the president...and his top officials met at the White House on April 10 with seven private scientists in the Truman Room, where Cabinet meetings are held. For an hour, participants say, the scientists discussed the germ topic and pushed for a vaccine stockpile. Clinton's attending officials included the secretary of defense, the attorney general, the secretary of health and human services, the director of Central Intelligence and the president's national security adviser. The scientists present were Dr. Frank Young, a former head of the Food and Drug Administration, who moderated the panel; Dr. Joshua Lederberg, president emeritus of Rockefeller University; Dr. Lucille Shapiro, a biologist at Stanford University; Jerome Hauer, head of emergency management for New York City; and Dr. Barbara Rosenberg, a biological arms-control expert at the Federation of American Scientists, a private group. The scientific panel also had two industry experts, both with financial ties to vaccine work. ..Dr. Thomas Monath was identified in a White House announcement as a vice president of OraVax and a former official of the Centers for Disease Control and the U.S. Army Medical Research Institute of Infectious Diseases, the government's top body for defensive germ-warfare studies...Based in Cambridge, Mass., OraVax was founded in 1990 to tap an emerging multi-billion-dollar market in oral vaccines and antibodies to combat infectious diseases. But the small company kept having problems getting beyond research and bringing products to market. By 1996 and 1997, its survival at stake, OraVax tried to win part of the Pentagon's expanding germ work as a subcontractor to make smallpox and other vaccines. By early this year, that work had failed to materialize and the company's stock price was down 90 percent from $10 a share in the initial public offering...."The way to handle it is to be open, so people understand that I may have a potential bias," Monath said. "I don't make it a business of taking advantage of situations in which I'm asked to participate to push the OraVax agenda." _____
(Note how the VP of Oravax, manufacturer of the encephalitis vaccine who is advising Giuliani on this crisis, was both a researcher at Ft. Dietrick Bio-Warfare lab and a CDC scientist.)
"Thomas Monath is one of the world's leading arbovirologists. He is currently Vice- President of Research and Medical Affairs at OraVax, Inc. in Cambridge, Massachusetts. In this position he is responsible for the scientific direction of programs on vaccine development...Prior to this he was the Chief of the Virology Division, U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick in Maryland. In this position he was responsible for the development of genetically engineered vaccines against arthropod- borne and hemorrhagic fever viruses. Between 1974 and 1988 he was the Medical Director of the Division of Vector- Borne Infectious Diseases at the Centers for Disease Control in Fort Collins, Colorado." _____
From Patricia Doyle
Here is the way the article appears on the Peptide Theraputic website:
Peptide awarded grant by NIH to develop West Nile vaccine
Cambridge, UK - 1 August 2000 - Peptide Therapeutics Group ("Peptide") announces that it s US subsidiary, OraVax Inc. has been awarded a Fast-Track Small Business Innovative Research (SBIR) grant by the US National Institutes of Health ("NIH") to develop an important new vaccine to prevent West Nile virus disease ("West Nile").
West Nile is a mosquito-borne viral disease that can be fatal. The disease first occurred in the US in the summer of 1999, when an outbreak occurred in New York in which 62 people were hospitalised with encephalitis and seven people died. Based on antibody surveys, approximately 2.5% of New York metropolitan residents were infected, making it likely that many had developed milder illnesses. Countless wild birds and a number of horses also succumbed to the disease. Other US states affected were New Jersey, Connecticut and Maryland. Several preventative measures were taken last year, including the spraying of New York City with pesticide in an attempt to kill the infected mosquitoes.
Fears are growing that another outbreak could occur this year. Infected birds and mosquitoes have been detected over a wide area from New Jersey to Massachusetts. Public health warnings have been issued to residents of the affected States, and intensive mosquito control is underway in many areas. There is no vaccine, cure or specific therapy against West Nile virus disease. The US government is actively pursuing a campaign to combat the disease, including funding the development of vaccines for preventative use.
The grant has been awarded through Peptide's US subsidiary, OraVax Inc. Funding under the NIH SBIR grant is provided in two consecutive Phases, and the Fast-track mechanism ensures no delay between Phases. The Phase 1 award, covering the first 8 months of work is for $263K. Following successful completion of Phase1, Phase 2 of the grant will be funded at a level of $2.7M for up to two years. The Fast-Track grant is expected to cover the costs of research and development, including initial human clinical trials.
The West Nile vaccine will be developed using Peptideís proprietary ChimeriVax&trade; technology. It will be a live, attenuated vaccine and involves the construction of a chimeric virus in which the envelope genes of yellow fever vaccine are replaced with the corresponding genes of the target West Nile virus. This approach has already been employed by Peptide to develop vaccines against dengue fever (in pre-clinical development) and Japanese encephalitis (due to commence Phase I trials shortly).
Dr Thomas Monath, Vice President Research & Medical Affairs of Peptide, said: "The advantages of ChimeriVax&trade; vaccines include their high safety profile, ability to induce protection within a few days after a single dose, and long-lasting immunity without the need for booster doses. A ChimeriVax&trade; West Nile vaccine is therefore ideally suited for use in an impending epidemic, where rapid immunization is required."
Dr John Brown, Chief Executive of Peptide, said: "We are delighted to have been selected by the US government to receive funding to continue to develop our West Nile vaccine. The West Nile virus is one of the most frightening to have emerged in recent years and there is no vaccine available to protect against the disease. We are confident that ChimeriVax&trade; can provide the technology to develop a vaccine that will provide a rapid and effective solution." _____
Enquiries: Peptide Therapeutics Group plc
Dr John Brown, Chief Executive Tel: + 44 1223 275300
Dr Thomas Monath, Vice President Research & Medical Affairs Tel: +1 617 494 1339
Web site: Financial Dynamics David Yates/Sophie Pender-Cudlip Tel: +44 207 831 3113
Notes to Editors
1. Peptide
Peptide is a biopharmaceutical company developing vaccines to prevent and treat infectious diseases. It is based in Cambridge, UK and, through its subsidiary OraVax Inc., has operations in Cambridge, Massachusetts. It has a broad portfolio of vaccine product candidates undergoing clinical trials and several technology platforms that provide the basis for further vaccine product candidates. For further information visit our web site at
2. ChimeriVax&trade;
The ChimeriVax&trade; technology platform is a method for development of new vaccines against viruses in the family Flaviviridae. The technology utilizes a molecular clone of yellow fever 17D, one of the safest and most effective vaccines ever developed, as the foundation for construction of new live, attenuated vaccines against related Flaviviruses. To generate a new vaccine, the genes for the viral envelope of yellow fever 17D virus are replaced with the corresponding genes of the target virus, for example West Nile, creating a yellow fever-West Nile hybrid or ëchimeraí. The new virus contains West Nile envelope proteins required for stimulating immunity but retains the replicative machinery of yellow fever 17D vaccine virus.
The ChimeriVax&trade; technology is being developed in several product programmes including vaccines against dengue fever, Japanese encephalitis, tick-borne encephalitis and hepatitis C. Peptideís most advanced programme using this technology is to develop a vaccine against Japanese encephalitis, the leading cause of viral infection of the central nervous system in Asia. Phase I trials are scheduled to commence shortly.
3. West Nile
West Nile encephalitis is a mosquito-borne disease that can cause inflammation of the spinal cord and brain and can be fatal. The virus that causes West Nile encephalitis occurs in Europe, Africa and Asia and was first identified in the United States in the summer of 1999. The virus grows in birds and is transmitted by mosquitoes from birds to humans and other mammals such as horses and cows.
There is no vaccine, cure or specific therapy for West Nile encephalitis. Whilst some of the symptoms of the disease can be treated, approximately 7% of people who are hospitalised from the infection die from it. _____
Area Labs Have Long Studied Virus Yale, Rockefeller Began Tests In '50s
Newday 9-29-99
" Epidemiologists suspect that the West Nile virus has for the first time been isolated in humans or animals in the Western Hemisphere, but the virus has for decades made its home in several U.S. research laboratories, including Rockefeller University in Manhattan and Yale University in New Haven, Conn. In fact, investigators there were the first to grow and study the West Nile virus in the United States. The work began in the 1950s when unidentified viral samples from around the world arrived at Rockefeller on a steady basis."
Mosquito From Asia Could Carry West Nile
Newsday 5-9-00
(AP) - In Army tests at Fort Detrick in Frederick, Md., japonicus was found to be the "most competent vector" [transmittter] for West Nile virus in a laboratory setting, when compared with other mosquitoes."
From: [from Federal Register: March 22, 1996 (Volume 61, Number 57, Page 11812] DEPARTMENT OF DEFENSE Notice of Intent To Grant an Exclusive License of a U.S. Government-Owned Patent Agency: U.S. Army Medical Research and Materiel Command, DOD [Department of Defense]. Action: Notice.
In accordance with 37 CFR 404.7 (a)(I)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license of U.S. Patent Application Serial Number 08/348,882, filed November 28, 1994 and entitled ``Infectious DNA Clones of Japanese Encephalitis Virus and Attenuated Strains Japanese Encephalitis Virus Made from the Clones'', to OraVax, Inc., 230 Albany Street, Cambridge, Massachusetts 02139. [Requests to the Army for further information should be directed to the public affairs officer, Mr. Chuck Dasey (301) 619-2736]
Robert Lederman, President of A.R.T.I.S.T. (Artists,Äô Response To Illegal State Tactics) (718) 743-3722 For an article on the Manhattan Institute go to
If you would like to help oppose the spraying, please write to the No Spray Coalition, PO Box 334, Peck Slip Station, NYC 10272-0334, or call the No Spray hotline at (718) 670-7110. Any funds you can send to help continue the lawsuit and this work are greatly appreciated.
For Lederman articles with more on this information see _____
Bugged by Spraying
Newsday 10-10-99
The loudest protests heard during the city's recent campaign of insecticide spraying came from the city's tiny Green Party and the artist-agitator Robert Lederman...Yesterday, the head of the mayor's Office of Emergency Management, which took the lead in the assault on the city's mosquito populace, dismissed such concerns as "irresponsible environmental hysteria and stupidity." "If they took a deep breath [of Malathion?] and looked at what we did and what pains we went through to ensure that we did it right and recognize that human life is at stake, they'd get the perspective," said OEM Director Jerry Hauer.,Äù _____
Date: Wed 8-2-00
Subject: Fwd: Award granted for W. Nile vaccine
BETHESDA, Md. - The National Institutes of Health has awarded a Massachusetts biotechnology firm $3 million to try to create a vaccine for the potentially fatal West Nile virus. Tuesday,Äôs announcement comes as several Northeastern states are trying to educate the public about the disease and kill mosquitoes that carry it.
The virus killed seven people and sickened more than 60 in the New York City area last year, its first appearance in the Western Hemisphere.
The company, OraVax Inc., plans to develop the West Nile vaccine using a proven 60-year-old yellow fever vaccine.
"This is a live viral vaccine like one for measles or mumps or polio," said Thomas Monath, OraVax,Äôs vice president of research and medical affairs. ,ÄúIt will cause a very mild infection with no symptoms and leave the person immunized against West Nile.,Äù Monath said human testing could begin within 18 months.
OraVax, a Cambridge, Mass.-based subsidiary of Britain,Äôs Peptide The virus killed seven people and sickened more than 60 in the New York City area last year, its first appearance in the Western Hemisphere. Therapeutics Group, has been working on a West Nile vaccine since last fall.
No human deaths have been reported this year, but mosquitoes carrying the virus have been found in parts of New York, and the virus has shown up in birds there and elsewhere in the Northeast.

This Site Served by TheHostPros